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Abstract
Objective: A distinctive pattern of physiological symmetrical uptake of 18F-fluorodeoxyglucose
(18F-FDG) in the neck and upper chest region is a phenomenon that is sometimes observed on
positron emission tomography (PET) scans of some oncologic patients. Initially, it was assumed
to be muscle uptake secondary to patient anxiety or tension, which could be prevented by
diazepam treatment. However, PET–computed tomography data have shown that 18F-FDG
uptake is not restricted to the musculature but is also localised within the non-muscular soft
tissue, such as brown adipose tissue. The efficacy of benzodiazepine treatment to reduce this
uptake has not been well established. Therefore, a randomised controlled trial was conducted to
decide whether diazepam would decrease physiological 18F-FDG uptake in the neck and upper
chest region (FDG-NUC).
Methods: A randomised, double-blind, placebo-controlled trial was conducted to assess the
effect on FDG-NUC of 5 mg diazepam, given orally 1 h before 18F-FDG injection. Patients
younger than 40 years, having or suspected to have a malignancy, were eligible for inclusion.
The primary endpoint was FDG-NUC, as assessed by visual analysis of whole-body PET scans
by two independent observers. The secondary endpoint was clinical relevance of FDG-NUC.
Results: Fifty-two patients were included between September 2003 and January 2005. Twenty-
eight patients (54%) received placebo; 24 (46%) received diazepam. FDG-NUC was seen in
25% of the patients in the diazepam group versus 29% in the placebo group. This difference was
not statistically significant.
Conclusion: No beneficial effect of administration of diazepam could be established. Pre-
medication with benzodiazepines to diminish physiological uptake of 18F-FDG in the neck and
upper chest region is not indicated.
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Introduction
Preparation of patients for
18F-fluorodeoxyglucose (18F-
FDG) positron emission tomography (PET) studies aims
to eliminate or reduce patterns of physiological uptake that
may interfere with image interpretation. Non-specific 18F-
FDG uptake in the neck and mediastinal area, in the heart,
bowel and urinary tract might lead to erroneous interpreta-
tion with potentially serious clinical consequences or useless
scans. Fasting is the only universally accepted standard
procedure before 18F-FDG injection, although the duration
of fasting may vary. There is hardly any uniformity with
respect to other procedures to reduce non-specific uptake.
This is likely due to the lack of compelling evidence that
interventions actually work.
Especially non-specific uptake of 18F-FDG in the neck
and upper chest region can significantly interfere with image
quality and image interpretation. At first, this distinctive
pattern of physiological symmetrical uptake of 18F-FDG in
the neck and upper chest region (FDG-NUC; Fig 1),
predominantly seen in some oncologic patients, was thought
to be muscle uptake secondary to patient anxiety or tension
[1, 2]. However, PET–computed tomography (PET-CT) data
have shown that 18F-FDG uptake is not only restricted to the
musculature but is also localised within the non-muscular
soft tissue, such as the brown adipose tissue (BAT) [3].
Recent literature suggests that pre-medication with beta
blockers may diminish uptake of 18F-FDG in BAT [4, 5].
However, it is still relatively common to pre-medicate
patients with benzodiazepines to reduce FDG-NUC. Since
the efficacy of benzodiazepine treatment before administra-
tion of 18F-FDG has not been well established yet, a
randomised controlled trial was conducted to decide whether
oral administration of diazepam would decrease FDG-NUC
in oncologic patients younger than 40 years.
Previously, retrospective analysis of PET images ac-
quired in 192 patients at our centre revealed an overall
prevalence of 31% [6]. In patients under 40 years, this
percentage was 35. Multivariate logistic regression showed a
strong inverse association between age and FDG-NUC. No
association between low body mass index and FDG-NUC
could be established. Both findings were also reported by
Bar-Shalom et al. [7] and Truong et al. [8]. In our
retrospective analysis, no protective effect of benzodiaze-
pines could be determined. However, occasionally, benzo-
diazepines were administered only shortly before injection
of 18F-FDG. Considering a time to maximum plasma
concentration of at least 15 to 30 min, the drug may not
have been effective during the early uptake period following
injection of 18F-FDG [9].
Methods
Study Population
The study was conducted in two hospitals: a university
medical centre and a general hospital in The Netherlands.
Patients aged between 18 and 40 years who were referred for
an oncologic 18F-FDG PET scan were eligible. Exclusion
criteria were diabetes mellitus, myasthenia gravis, severe
hepatic insufficiency, known allergy to benzodiazepines,
driving on the day of the PET imaging, and use of a
benzodiazepine within 7 days before the start of the study.
Study Design
The study was designed as a prospective, double-blind,
multicenter, randomised, placebo-controlled clinical trial.
The Internal Review Board of both participating hospitals
Fig. 1. Physiological uptake of FDG in the neck and upper chest region.
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approved the protocol. Informed consent was obtained in all
patients.
Randomisation in blocks of four and stratification
according to centre and tumour was performed centrally by
the Department of Pharmacy of the VU University Medical
Center. Diazepam 5 mg (Stesolid®) tablets were obtained
from Dumex, Hilversum, The Netherlands and placebo
(albochin) tablets from Interpharm, Den Bosch, The Nether-
lands. The tablets were identical to ensure blinding. Study
medication was packaged and blinded at the Department of
Pharmacy of the VU University Medical Center.
Eligible patients were asked to participate by their own
attending clinician, the nuclear medicine physician or by the
principle investigator. If all inclusion criteria had been met
and informed consent had been obtained, patients were
randomised. Patients were instructed to take study medica-
tion 1 h before injection of 18F-FDG.
PET imaging was performed according to standard
hospital procedure. All patients were injected after fasting
for at least 6 h, although patients were allowed and
encouraged to drink only water. All serum glucose levels
were within normal range at time of PET scanning. During
the whole procedure, room temperature was constant at
about 20°C. The scans were obtained 1 h after intravenous
injection of 370–500 MBq 18F-FDG. 18F-FDG was obtained
from Tyco Mallinckrodt, Petten, The Netherlands.
Data Analysis
The primary endpoint was FDG-NUC prevalence, as
assessed by visual analysis of whole-body PET scans by
two independent experienced observers. Assessment of
abnormal FDG-NUC was performed using a Likert scale
(uptake absent, slight, moderate, and intense) to indicate the
intensity. Moderate and intense uptake were considered
positive for FDG-NUC, whereas absent and slight uptake
were deemed negative. The secondary endpoint was whether
FDG-NUC had any clinical relevance by interfering with
scan interpretation, as assessed by the observers. Clinical
relevance relates to the perceived probability of findings of
FDG-NUC to be interpreted by the nuclear medicine
physician as either false positive or false negative. This
clinical relevance was scaled as not relevant, moderately or
highly interfering with scan interpretation. In case of
disagreement on either endpoint, a third observer would
review the scan and serve as an arbiter.
Statistical Analysis
The number of patients needed was estimated from results of
the retrospective analysis earlier performed at the VU
University Medical Center [6]. The calculation was based
on a risk of FDG-NUC in patients under 40 years of 35%, a
drug-related improvement of 70%, which we thought was
clinically relevant and was realistic given the data of
Barrington et al. [1], a significance level of 0.05, a power
of 80% and two-tailed analysis. The number of patients
needed was calculated at 41 per treatment group.
Patients randomised 
(n=54) 
Patients treated 
(n=52) 
Evaluable patients 
Diazepam (n=24) 
Evaluable patients 
Placebo (n=28) 
not treated (n=2,1 withdrawn,   
1 inevaluable scan for other reason)  
Fig. 2. Flowchart of randomised patients.
Table 1. Patient characteristics
Treatment group p value
Placebo (n=28) Diazepam (n=24)
Sex (M/F) 15/13 12/12 0.797
Mean age (year)±SD 30.2±5.9 30.6±6.4 0.748
Mean bodyweight (kg)±SD 73.8±13.2 80.1±19.0 0.541
Mean body mass index (kg/m2)±SD 23.7±3.2 25.0±4.9 0.545
Scan 0.113
First (%) 20 (71) 12 (50)
Second or later (%) 8 (29) 12 (50)
Tumour 0.388
Head and neck (%) 0 (0) 1 (4)
Lymphoma (%) 15 (54) 15 (63)
Other (%) 13 (46) 8 (33)
Centre 0.377
VU University Medical Center, Amsterdam 25 23
Catharina Hospital, Eindhoven 3 1
Patients without co medication (%) 14 (50) 14 (58) 0.548
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Statistical analysis (Fisher exact chi-square) was per-
formed using SPSS 12.0, and pG0.05 was considered
statistically significant. For FDG-NUC in both groups,
95% exact binomial confidence intervals (95% CI) were
computed using STATA 8.0.
Results
Fifty-two patients were included in the study between
September 2003 and January 2005. Twenty-eight patients
(54%) received placebo and 24 (46%) diazepam (Fig. 2).
There was no difference in patient characteristics in the two
treatment groups (Table 1).
Six (25.0%; 95% CI, 9.8–46.7) patients in the diazepam
group developed FDG-NUC versus eight (28.6%; 95% CI,
13.2–48.7) in the placebo group (Table 2). The percentage
difference is not statistically significant (−3.6%; 95% CI,
−0.26–0.20, p=0.77). Table 3 shows the clinical relevance
of FDG-NUC in the patients. Since the calculated relative
risk of FDG-NUC was 0.88, approximately 2,500 patients
should be included to show a statistically significant
difference between diazepam and placebo. Therefore, the
study was stopped before inclusion was complete.
Co-medication was used by 14 of 28 (50%) patients in
the placebo group and ten of 24 (42%) patients in the
diazepam group (Table 4). Interactions between study
medication and co-medication were not clinically relevant.
Discussion
In this randomised clinical trial, diazepam had no effect on
the prevalence of FDG-NUC. In an earlier retrospective
study, we found that 35% of patients with malignant
lymphoma or malignancies of head and neck, thyroid or
lung younger than 40 years had FDG-NUC. In this
prospective study, the prevalence of FDG-NUC was slightly
lower at 27%. This may be explained by the difference in
patient population: For instance, patients with other tumour
types were allowed to enroll, and there may have been a
selection bias in favour of less anxious patients. Conceptu-
ally, this observed lack of a protective effect by diazepam is
in accordance with the idea that uptake of 18F-FDG is
primarily noted in non-muscular tissue, which might not be
blocked by benzodiazepines. This is in keeping with the
results of the preclinical studies described by Tatsumi et al.
The use of the non-selective beta-blocker propranolol
appeared to diminish uptake of 18F-FDG in BAT [4].
Furthermore, a case report has been published in which the
beneficial effect of propranolol has been described [5].
One might argue that the dose of diazepam, 5 mg, was
too low and therefore not effective. However, as none of the
patients was a regular benzodiazepine user, it is unlikely that
the low dose is the cause of the observed lack of effect in the
present study. Furthermore, Barrington and Maisey [1] used
doses ranging from 5 to 10 mg of diazepam as well.
An increasing number of institutions use PET-CT, with
less interpretation problems in physiological cervical uptake
due to the anatomical CT information. However, many
hospitals still use stand-alone PET systems. In either case, it
would be beneficial to be able to diminish physiological
uptake of 18F-FDG in patients who are at risk for FDG-
NUC. As we did not use a PET-CT combination, it was very
difficult to differentiate between uptake of FDG in brown fat
or muscle tissue. In most patients (12/14), the uptake was
bilateral, symmetrical and diffuse, indicating that this may
be in part muscle uptake [10]. The results of the present
study clearly show that benzodiazepines cannot be used to
Table 2. Physiological uptake of 18F-FDG in the neck and upper chest
region
Treatment group p value
Placebo (n=28) Diazepam (n=24)
No FDG-NUC (%) 20 (71) 18 (75) 0.772
FDG-NUC (%) 8 (29) 6 (25)
Table 3. Clinical relevance of FDG-NUC in patients showing physiological
uptake in neck and upper chest region
Treatment group p value
Placebo (n=8) Diazepam (n=6)
Not relevant (%) 8 (100) 4 (67) 0.165
Moderately relevant (%) 0 (0) 1 (17)
Highly relevant (%) 0 (0) 1 (17)
Table 4. Co-medication taken by patients in the treatment groups
Treatment group
Placebo (n=28) Diazepam (n=24)
Patients with co-medication (%) 14 (50) 10 (42)
Co-medication (%):
Analgesics
Acetaminophen 1 (4) 0 (0)
Rofecoxib 1 (4) 0 (0)
Anticoagulants
Acenocoumarol 1 (4) 0 (0)
Nadroparine (s.c.) 1 (4) 0 (0)
Blood products
Darbepoetin alpha (s.c.) 0 (0) 1 (4)
Filgrastim (s.c.) 2 (7) 1 (4)
Corticosteroids
Fluticason (per inhalation) 1 (4) 0 (0)
Prednisolone 0 (0) 1 (4)
Gastrointestinal drugs
Ondansetron 1 (4) 2 (8)
Pantoprazole 2 (7) 0 (0)
Polyethylene glycol 0 (0) 1 (4)
Hormonal contraceptives 1 (4) 1 (4)
Other
Antibacterial (co-trimoxazole) 3 (11) 2 (8)
Antidepressant (fluoxetine) 1 (4) 0 (0)
Antihistamine (clemastine) 1 (4) 0 (0)
Antineoplastic (procarbazine) 0 (0) 1 (4)
Antivirals (HIV cocktail) 0 (0) 1 (4)
Cardiovascular drug (lisinopril) 1 (4) 0 (0)
Medication was taken orally, unless otherwise specified
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diminish FDG-NUC, regardless of the origin of the uptake.
As benzodiazepines are muscle relaxants, these data also
suggest that interventions should focus on reducing uptake
of 18F-FDG in BAT, rather than in muscle. In our study, the
rooms were adequately acclimatised and warm. To confirm
the findings of Jacobsson et al. [5], it might be better to
focus on other interventions such as pre-medication with
beta blockers. Before such interventions can be imple-
mented, randomised controlled trials are necessary to show
the interventions to be effective on diminishing disturbing
physiological 18F-FDG uptake.
In conclusion, pre-medication with diazepam did not
reduce the prevalence of physiological uptake of 18F-FDG in
the neck and upper chest region.
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